Cancer Family
Mast Cell Neoplasm
CI-CAN-00000257Explore in graph →
HematologicNon-malignant9 active trials2 approved drugs4 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000257Explore in graph →
Clinical trials
101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03779854 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04910685 | (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | recruiting | Phase 2 / Phase 3 | 534 | Blueprint Medicines CorporationINDUSTRY | 23 | Sep 23, 2026 |
| clinicaltrials |
| NCT00044122 | Study of Factors Regulating Mast Cell Proliferation | recruiting | — | 700 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04996875 | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | recruiting | Phase 2 | 140 | Cogent Biosciences, Inc.INDUSTRY | 14 | Sep 15, 2026 | clinicaltrials |
| NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome | not yet recruiting | Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07264959 | An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) | recruiting | — | 150 | Blueprint Medicines CorporationINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06210698 | Angioedema Biomarker Research Study | recruiting | — | 600 | Foundation For Rare Disease ResearchOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07757893 | Precision Medicine for Indolent Systemic Mastocytosis (PRISM)(PRISM) | not yet recruiting | — | 25 | Mayo ClinicOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05362773 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | active not recruiting | Phase 1 | 130 | MacroGenicsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05186753 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | active not recruiting | Phase 2 | 237 | Cogent Biosciences, Inc.INDUSTRY | 15 | May 22, 2026 | clinicaltrials |
| NCT07562542 | Peripheral Blood KIT-D816V Mutation in Adult Systemic Mastocytosis(PB-KIT in SM) | recruiting | — | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07255638 | A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany | recruiting | — | 80 | Blueprint Medicines CorporationINDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06327685 | Avapritinib With Decitabine in Patients With SM-AHN | recruiting | Phase 1 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06748001 | Avapritinib Rollover Study | recruiting | Phase 4 | 60 | Blueprint Medicines CorporationINDUSTRY | 6 | Feb 9, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06573723 | Institutional Registry of Rare Diseases | recruiting | — | 380 | Hospital Italiano de Buenos AiresOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07328178 | Analysis of the Role of IgE Proteoforms in Health and Disease(IgE-PhD) | recruiting | — | 200 | KU LeuvenOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT03731260 | (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis | active not recruiting | Phase 2 | 251 | Blueprint Medicines CorporationINDUSTRY | 13 | Sep 23, 2025 | clinicaltrials |
| NCT07142473 | Mastocytosis From Pediatric Age to Adulthood: Local Registry of Cutaneous and Systemic Mastocytosis(MaRe) | recruiting | — | 600 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06065007 | Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis | active not recruiting | — | 400 | Uppsala UniversityOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT02760238 | Myeloproliferative Neoplasms (MPNs) Patient Registry | recruiting | — | 5,000 | University Health Network, TorontoOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06466889 | Mastocytosis Registry (of Zurich)(MastoR) | recruiting | — | 400 | University of ZurichOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06440148 | Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis | recruiting | — | 50 | Medical University of LublinOTHER | 1 | Jun 3, 2024 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials